WO2003059327A1 - Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof - Google Patents

Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof Download PDF

Info

Publication number
WO2003059327A1
WO2003059327A1 PCT/EP2002/000395 EP0200395W WO03059327A1 WO 2003059327 A1 WO2003059327 A1 WO 2003059327A1 EP 0200395 W EP0200395 W EP 0200395W WO 03059327 A1 WO03059327 A1 WO 03059327A1
Authority
WO
WIPO (PCT)
Prior art keywords
tablet
spray
bilayer
telmisartan
bilayer pharmaceutical
Prior art date
Application number
PCT/EP2002/000395
Other languages
French (fr)
Inventor
Thomas Friedl
Gottfried Schepky
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8164784&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003059327(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority to AU2002242676A priority Critical patent/AU2002242676B2/en
Priority to EP10179142A priority patent/EP2260833B1/en
Priority to SK290-2004A priority patent/SK288439B6/en
Priority to CA2651604A priority patent/CA2651604C/en
Priority to DK02708290.8T priority patent/DK1467712T4/en
Priority to YU61104A priority patent/RS52012B/en
Priority to PT101791424T priority patent/PT2260833E/en
Priority to MEP-2008-424A priority patent/ME02761B/en
Priority to IL16275402A priority patent/IL162754A0/en
Priority to KR1020087003317A priority patent/KR100876302B1/en
Priority to CA002472392A priority patent/CA2472392C/en
Priority to DK07115060.1T priority patent/DK1854454T3/en
Priority to CZ20040939A priority patent/CZ303145B6/en
Priority to JP2003559490A priority patent/JP4181503B2/en
Priority to EA200400879A priority patent/EA007614B1/en
Priority to UA20040806794A priority patent/UA78273C2/en
Priority to DE60224096T priority patent/DE60224096T3/en
Priority to KR1020047011113A priority patent/KR100851770B1/en
Priority to NO20171988A priority patent/NO345891B1/en
Priority to HU0501086A priority patent/HU229941B1/en
Priority to CNA2008102144454A priority patent/CN101352421A/en
Priority to NZ534502A priority patent/NZ534502A/en
Priority to EP07115060.1A priority patent/EP1854454B1/en
Priority to CNB028271823A priority patent/CN100571695C/en
Priority to EA200601917A priority patent/EA012329B1/en
Priority to PT02708290T priority patent/PT1467712E/en
Priority to BR0215514-1A priority patent/BR0215514A/en
Priority to MXPA04006997A priority patent/MXPA04006997A/en
Priority to SI200230664T priority patent/SI1467712T2/en
Priority to AT02708290T priority patent/ATE380547T1/en
Priority to PCT/EP2002/000395 priority patent/WO2003059327A1/en
Priority to ES02708290T priority patent/ES2298351T5/en
Priority to EP02708290A priority patent/EP1467712B2/en
Priority to PT71150601T priority patent/PT1854454E/en
Priority to ES07115060.1T priority patent/ES2445041T3/en
Priority to ES10179142T priority patent/ES2400138T3/en
Priority to DK10179142.4T priority patent/DK2260833T3/en
Publication of WO2003059327A1 publication Critical patent/WO2003059327A1/en
Priority to IL162754A priority patent/IL162754A/en
Priority to BG108781A priority patent/BG66524B1/en
Priority to US10/892,425 priority patent/US20050089575A1/en
Priority to HR20040649 priority patent/HRP20040649B1/en
Priority to NO20043344A priority patent/NO342634B1/en
Priority to HK05106429.3A priority patent/HK1073785A1/en
Priority to CY20081100247T priority patent/CY1107226T1/en
Priority to JP2008180150A priority patent/JP4929241B2/en
Priority to AU2008203182A priority patent/AU2008203182B2/en
Priority to IL194933A priority patent/IL194933A/en
Priority to US12/464,957 priority patent/US20090227802A1/en
Priority to IL219481A priority patent/IL219481A/en
Priority to CY20131100140T priority patent/CY1114929T1/en
Priority to US13/947,429 priority patent/US20130309307A1/en
Priority to CY20141100062T priority patent/CY1114890T1/en
Priority to NO20140821A priority patent/NO336167B1/en
Priority to BG112153A priority patent/BG66588B1/en
Priority to BG112220A priority patent/BG67075B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to a bilayer pharmaceutical tablet formulation comprising the angiotensin II receptor antagonist telmisartan in combination with a diuretic such as hydrochlorothiazide (HCTZ).
  • HCTZ hydrochlorothiazide
  • the present invention also provides a method of producing said bilayer tablet.
  • INN Telmisartan is an angiotensin II receptor antagonist developed for the treatment of hypertension and other medical indications as disclosed in EP-A-502314.
  • Telmisartan is generally manufactured and supplied in the free acid form. It is characterized by its very poor solubility in aqueous systems at the physiological pH range of the gastro-intestinal tract of between pH 1 to 7. As disclosed in WO 00/43370, crystalline telmisartan exists in two polymorphic forms having different melting points. Under the influence of heat and humidity, the lower melting polymorph B transforms irreversibly into the higher melting polymorph A. Hydrochlorothiazide (HCTZ) is a thiazide diuretic which is orally administered in the treatment of edema and hypertension.
  • HCTZ Hydrochlorothiazide
  • HCTZ 6-chloro-3,4-dihydro-2H-1 ,2,4-benzothiadiazine- 7-sulfonamide-1 ,1 -dioxide having the following structure
  • Combination therapy of telmisartan with a diuretic like HCTZ is expected to show synergistic therapeutic efficacy in the treatment of hypertension.
  • a fixed-dose combination of drugs intended for immediate release is prepared by either making a powder mixture or a co-granulate of the two active ingredients with the necessary excipients, normally keeping the basic formulation of the corresponding mono-drug preparation and simply adding the second drug component.
  • telmisartan With a combination of telmisartan and HCTZ, this approach was not feasible due to the incompatibility of HCTZ with basic compounds such as, e.g., meglumine (N- methyl-D-glucamine) which is a component of conventional telmisartan formulations, and the reduced dissolution rate of HCTZ from a dissolving matrix as compared with dissolution from a disintegrating tablet.
  • basic compounds such as, e.g., meglumine (N- methyl-D-glucamine) which is a component of conventional telmisartan formulations
  • a classical approach is to coat the HCTZ particles in a fluidized-bed granulator with a polymer solution containing water soluble polymers . like hydroxypropylcellulose, hydroxypropylmethylcellulose or polyvinylpyrrolidone, thereby reducing the contact surface area of the HCTZ particles with the telmisartan formulation during mixing and compressing. Yet, by these means it was not possible to reduce the contact area of HCTZ with the telmisartan formulation in a compressed tablet to a degree sufficient to achieve the desired prolonged shelf life.
  • telmisartan and HCTZ were produced separate film-coated tablets for telmisartan and HCTZ in such a size and shape that these could be filled into a capsule.
  • a capsule of size 1 to 0 long could be filled.
  • the drug dissolution rate of telmisartan was reduced compared to the single entities due to a lag-time effect of the large capsule shells.
  • a zero long capsule is not deemed reliable.
  • telmisartan in substantially amorphous form in a dissolving tablet matrix
  • a second layer containing a diuretic in a disintregrating tablet matrix in accordance with the present invention, is has now been found that the above- described problems associated with conventional approaches in the preparation of a fixed dose combination drug comprising telmisartan and a diuretic could be overcome by means of a bilayer pharmaceutical tablet comprising a first layer containing telmisartan in substantially amorphous form in a dissolving tablet matrix, and a second layer containing a diuretic in a disintregrating tablet matrix.
  • the bilayer tablet according to the present invention provides a largely pH- independent dissolution of the poorly water-soluble telmisartan, thereby facilitating dissolution of the drug at a physiological pH level, and also provides for immediate release of the diuretic from the fast disintegrating matrix.
  • the bilayer tablet structure overcomes the stability problem caused by the incompatibility of diuretics like HCTZ with basic constitutents of the telmisartan formulation.
  • the present invention relates to an improvement in bilayer tableting technology and provides a method of producing a bilayer pharmaceutical tablet comprising the steps of: (i) providing a first tablet layer composition by a) preparing an aqueous solution of telmisartan, at least one basic agent and, optionally, a solubilizer and/or a crystallization retarder; b) spray-drying said aqueous solution to obtain a spray-dried granulate; c) mixing said spray-dried granulate with a water-soluble diluent to obtain a premix; d) mixing said premix with a lubricant to obtain a final blend for the first tablet layer; e) optionally, adding other excipients and/or adjuvants in any of steps a) to d); (ii) providing a second tablet layer composition by f) mixing and/or granulating a diuretic with the constituents of a disintegrating tablet matrix and, optionally, further excipient
  • substantially amorphous refers to a product comprising amorphous constituents in a proportion of at least 90%, preferably at least 95%, as determined by X-ray powder diffraction measurement.
  • dissolving tablet matrix refers to a pharmaceutical tablet base formulation having immediate release (fast dissolution) characteristics that readily dissolves in a physiological aqueous medium.
  • diuretic refers to thiazide and thiazide-analogue diuretics like hydrochlorothiazide (HCTZ), clopamide, xipamide or chlorotalidone, and any other diuretic suitable in the treatment of hypertension like, e.g., furosemide and piretanide, and combinations thereof with amiloride and triamteren.
  • disintegrating tablet matrix refers to a pharmaceutical tablet base formulation having immediate release characteristics that readily swells and disintegrates in a physiological aqueous medium.
  • the bilayer tablet according to the present invention comprises a first layer containing telmisartan in substantially amorphous form in a dissolving tablet matrix, and a second layer containing a diuretic in a disintregrating tablet matrix.
  • telmisartan is generally supplied in its free acid form, although pharmaceutically acceptable salts may also be used. Since during subsequent processing telmisartan is normally dissolved and transformed into a substantially amorphous form, its initial crystal morphology and particle size are of little importance for the physical and biopharmaceutical properties of the bilayer tablet formulation obtained. It is however preferred to remove agglomerates from the starting material, e.g. by sieving, in order to facilitate wetting and dissolution during further processing.
  • Substantially amorphous telmisartan may be produced by any suitable method known to those skilled in the art, for instance, by freeze drying of aqueous solutions, coating of carrier particles in a fluidized bed, and solvent deposition on sugar pellets or other carriers.
  • the substantially amorphous telmisartan is prepared by the specific spray-drying method described hereinafter.
  • the other active ingredient i.e. the diuretic
  • the particle size distribution of hydrochlorothiazide as determined by the method of laser light scattering in a dry dispersion system (Sympatec Helos/Rodos, focal length 100 mm) is preferably as follows: io ⁇ 20 ⁇ m, preferably 2 to 10 ⁇ m dso 5 to 50 ⁇ m, preferably 10 to 30 ⁇ m dgo 20 to 100 ⁇ m, preferably 40 to 80 ⁇ m
  • the bilayer tablet according to the present invention generally contains 10 to 160 mg, preferably 20 to 80 mg, of telmisartan and 6.25 to 50 mg, preferably 12.5 to 25 mg, of diuretic.
  • Presently preferred forms are bilayer tablets comprising 40/12.5 mg, 80/12.5 mg and 80/25 mg of telmisartan and HCTZ, respectively.
  • the first tablet layer contains telmisartan in substantially amorphous form dispersed in a dissolving tablet matrix having immediate release (fast dissolution) characteristics.
  • the dissolving tablet matrix may have acidic, neutral or basic properties, although a basic tablet matrix is preferred.
  • the dissolving matrix comprises a basic agent, a water-soluble diluent and, optionally, other excipients and adjuvants.
  • suitable basic agents are alkali metal hydroxides such as NaOH and KOH; basic amino acids such as arginine and lysine; and meglumine (N- methyl-D-glucamine), NaOH and meglumine being preferred.
  • suitable water-soluble diluents are carbohydrates such as monosaccharides like glucose; oligosaccharides like sucrose, anhydrous lactose and lactose monohydrate; and sugar alcohols like sorbitol, mannitol, dulcitol, ribitol and xylitol. Sorbitol is a preferred diluent.
  • excipients and/or adjuvants are, for instance, selected from binders, carriers, fillers, lubricants, flow control agents, crystallization retarders, solubilizers, coloring agents, pH control agents, surfactants and emulsifiers, specific examples of which are given below in connection with the second tablet layer composition.
  • the excipients and/or adjuvants for the first tablet layer composition are preferably chosen such that a non-acidic, fast dissolving tablet matrix is obtained.
  • the first tablet layer composition generally comprises 3 to 50 wt.%, preferably 5 to 35 wt.%, of active ingredient; 0.25 to 20 wt.%, preferably 0.40 to 15 wt.%, of basic agent; and 30 to 95 wt.%, preferably 60 to 80 wt.% of water-soluble diluent.
  • constituents may, for instance, be chosen from one or more of the following excipients and/or adjuvants in the amounts indicated:
  • 0.1 to 5 wt.% preferably 0.5 to 3 wt.%, of lubricants; 0.1 to 5 wt.%, preferably 0.3 to 2 wt.%, of flow control agents;
  • pH control agents 0.5 to 10 wt.%, preferably 2 to 8 wt.%, of pH control agents
  • the second tablet layer composition contains a diuretic in a fast disintegrating tablet matrix.
  • the disintegrating tablet matrix comprises a filler, a binder, a disintegrant and, optionally, other excipients and adjuvants.
  • the filler is preferably selected from anhydrous lactose, spray-dried lactose and lactose monohydrate.
  • the binder is selected from the group of dry binders and/or the group of wet granulation binders, depending on the manufacturing process chosen for the second tablet layer.
  • Suitable dry binders are, e.g., cellulose powder and microcrystalline cellulose.
  • Specific examples of wet granulation binders are corn starch, polyvinyl pyrrolidone (Povidon), vinylpyrrolidone-vinylacetate copolymer (Copovidone) and cellulose derivatives like hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose.
  • Suitable disintegrants are, e.g., sodium starch glycolate, Crospovidon, Croscarmellose, sodium carboxymethylcellulose and dried corn starch, sodium starch glycoiate being preferred.
  • the other excipients and adjuvants are preferably selected from diluents and carriers such as cellulose powder, microcrystalline cellulose, cellulose derivatives like hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose, dibasic calcium phosphate, corn starch, pregelatinized starch, polyvinyl pyrrolidone (Povidone) etc.; lubricants such as stearic acid, magnesium stearate, sodium stearylfumarate, glycerol tribehenate, etc.; flow control agents such as colloidal silica, talc, etc.; crystallization retarders such as Povidone, etc.; solubilizers such as Pluronic, Povidone, etc.; coloring agents, including dyes and pigments such as Iron Oxide Red or Yellow, titanium dioxide, talc, etc.; pH control agents such as citric acid, tartaric acid, fumaric acid, sodium citrate, dibasic
  • sodium phosphate, etc. surfactants and emulsifiers such as Pluronic, polyethylene glycols,. sodium carboxymethyl cellulose, polyethoxylated and hydrogenated castor oil, etc.; and mixtures of two or more of these excipients and/or adjuvants.
  • the second tablet layer composition generally comprises 1.5 to 35 wt.%, preferably 2 to 15 wt.%, of active ingredient; 25 to 75 wt.%, preferably 35 to 65 wt.%, of filler; 10 to 40 wt.%, preferably 15 to 35 wt.%, of dry binder; 0.5 to 5 wt.%, preferably 1 to 4 wt.%, of wet granulation binder; and 1 to 10 wt.%, preferably 2 to 8 wt.%, of disintegrant.
  • the other excipients and adjuvants are generally employed in the same amount as in the first tablet layer composition.
  • the first and second tablet layer compositions may be compressed in the usual manner in a bilayer tablet press, e.g. a high-speed rotary press in a bilayer tableting mode.
  • a bilayer tablet press e.g. a high-speed rotary press in a bilayer tableting mode.
  • the ratio of the compression force applied during compression of the first tablet layer to the compression force applied during compression of both the first and second tablet layers is in the range of from 1 :10 to 1:2.
  • the first tablet layer may be compressed at moderate force of 4 to 8 kN, whereas the main compression of first plus second layer is performed at a force of 10 to 20 kN.
  • the bilayer tablets obtained release the active ingredients rapidly and in a largely pH-independent fashion, with complete release occurring within less than 60 min and release of the major fraction occurring within less than 15 min.
  • the dissolution/- disintegration kinetics of the bilayer tablet may be controlled in different ways. For instance, both layers may dissolve/disintegrate simultaneously. Preferably, however, the second tablet layer containing the diuretic disintegrates first whereas the first tablet layer containing telmisartan dissolves in parallel or subsequently.
  • a substantially increased dissolution rate of the active ingredients and, in particular, of telmisartan is achieved. Normally, at least 70% and typically at least 90% of the drug load are dissolved after 30 min.
  • the bilayer tablets of the present invention tend to be slightly hygroscopic and are therefore preferably packaged using a moisture-proof packaging material such as aluminium foil blister packs, or polypropylene tubes and HDPE bottles which preferably contain a desiccant.
  • a specific method of producing the bilayer tablet according to the present invention comprises (i) providing a first tablet layer composition by a) preparing an aqueous solution of telmisartan, at least one basic agent and, optionally, a solubilizer and/or a crystallization retarder; b) spray-drying said aqueous solution to obtain a spray-dried granulate; c) mixing said spray-dried granulate with a water-soluble diluent to obtain a premix; d) mixing said premix with a lubricant to obtain a final blend for the first layer; e) optionally, adding other excipients and/or adjuvants in any of steps a) to d); (ii) providing a second tablet layer composition by f) mixing and /or granulating a diuretic with the constituents of a disintegrating tablet matrix and, optionally, further excipients and/
  • an aqueous alkaline solution of telmisartan is prepared by dissolving the active ingredient in purified water with the help of one or more basic agents like sodium hydroxide and meglumine.
  • a solubilizer and/or a recrystallization retarder may be added.
  • the dry matter content of the starting aqueous solution is generally 10 to 40 wt.%, preferably 20 to 30 wt.%.
  • the aqueous solution is then spray-dried at room temperature or preferably at increased temperatures of, for instance, between 50 and 100°C in a co-current or countercurrent spray-drier at a spray pressure of, for instance, 1 to 4 bar.
  • the spray-drying conditions are preferably chosen in such a manner that a spray-dried granulate having a residual humidity of ⁇ 5 wt.%, preferably ⁇ 3.5 wt.%, is obtained in the separation cyclone.
  • the outlet air temperature of the spray- drier is preferably kept at a value of between about 80 and 90°C while the other process parameters such as spray pressure, spraying rate, inlet air temperature, etc. are adjusted accordingly.
  • the spray-dried granulate obtained is preferably a fine powder having the following particle size distribution:
  • dio ⁇ 20 ⁇ m preferably ⁇ 10 ⁇ m d ⁇ o ⁇ 80 ⁇ m, preferably 20 to 55 ⁇ m dgo ⁇ 350 ⁇ m, preferably 50 to 150 ⁇ m
  • the active ingredient (telmisartan) as well as the excipients contained in the spray-dried granulate are in a substantially amorphous state with no crystallinity being detectable.
  • the spray-dried granulate is a solidified solution or glass having a glass transition temperature Tg of preferably > 50°C, more preferably > 80°C.
  • the spray-dried granulate preferably contains 5 to 200 parts by weight of basic agent and, optionally, solubilizer and/or crystallization retarder.
  • the water-soluble diluent is generally employed in an amount of 30 to 95 wt.%, preferably 60 to 80 wt.%, based on the weight of the first tablet layer composition.
  • the lubricant is generally added to the premix in an amount of 0.1 to 5 wt.%, preferably 0.3 to 2 wt.%, based on the weight of the first tablet layer composition.
  • Mixing is carried out in two stages, i.e. in a first mixing step the spray-dried granulate and the diluent are admixed using , e.g., a high-shear mixer or a free-fall blender, and in a second mixing step the lubricant is blended with the premix, preferably also under conditions of high shear.
  • the method of the invention is however not limited to these mixing procedures and, generally, alternative mixing procedures may be employed in steps c), d), and also in the subsequent steps f) and g), such as, e.g., container mixing with intermediate screening.
  • the second tablet layer composition may be prepared by dry-mixing the constituent components, e.g.
  • the second tablet layer composition is prepared using a wet granulation technique wherein an aqueous solution of a wet granulation binder is added to a premix and subsequently the wet granulate obtained is dried, e.g. in a fluidized-bed dryer or drying chamber. The dried mixture is screened and then a lubricant is admixed, e.g. using a tumbling mixer or free-fall blender, whereafter the composition is ready for compression.
  • the first and second tablet layer compositions are compressed in a bilayer tablet press, e.g. a rotary press in the bilayer tableting mode, in the manner described above.
  • a bilayer tablet press e.g. a rotary press in the bilayer tableting mode
  • any granulate residues have to be carefully removed during tableting by intense suction of the die table within the tableting chamber.
  • the solution is sprayed into a suitable spray dryer, e.g. a Niro P 6.3 equipped with Schlick atomizing nozzles of 1.0 mm diameter, with a flow-through heating coil connected upstream of the dryer, and dried to give a white to off-white fine granulate.
  • a suitable spray dryer e.g. a Niro P 6.3 equipped with Schlick atomizing nozzles of 1.0 mm diameter
  • the spray mode is counter-current at a spray-pressure of about 3 bar, an inlet air temperature of about 125°C and a spray rate of about 11 kg/h, thus resulting in an outlet air temperature of about 85°C.
  • the temperature of the flow through heating coil water bath is set at a temperature of about 80°C.
  • the dry granulate powder is screened through a screen of 0.5 mm mesh size, e.g. using a Vibra Sieve machine.
  • the resulting amorphous telmisartan spray-dried granulate may be further processed to telmisartan mono-tablets or the first layer of the said bilayer tablet composition.
  • the resulting wet granulate is dried in a suitable fluid bed dryer, e.g. Glatt WSG 120 at an inlet air temperature of 100°C, an inlet air flow of 2000-3000 m 3 /h until a product temperature of about 55°C is reached.
  • a suitable fluid bed dryer e.g. Glatt WSG 120 at an inlet air temperature of 100°C, an inlet air flow of 2000-3000 m 3 /h until a product temperature of about 55°C is reached.
  • the dry.granulate is screened to reduce the particle size using a suitable screening machine, e.g. a Comil screen machine equipped with a rasp screen of 2 mm mesh size. Finally 1.000 kg of prescreened magnesium stearate are admixed to the screened granulate material and mixed in a suitable tumbling mixer, e.g. a Lermer rotating spike mixer, for 100 revolutions at a speed of 8-10 rpm. 3.
  • a suitable tumbling mixer e.g. a Lermer rotating spike mixer
  • 240 kg of the final blend (A) and 200 kg of the final blend (B) are compressed into bilayer tablets.
  • the target weight for the first layer is 240 mg
  • the target weight for the second layer is 200 mg.
  • the tablet hardness is adjusted by variation of the main compression force of the second layer.
  • the second layer composition is manufactured by dry mixing of (09) to (13) in a suitable free fall blender, e.g. a i m 3 container mixer, for 200 revolutions at a speed of 10 rpm. Then, (08) is admixed to the main mixture for further 50 revolutions in the container mixer.
  • a suitable free fall blender e.g. a i m 3 container mixer
  • (08) is admixed to the main mixture for further 50 revolutions in the container mixer.
  • an additional premix with yellow iron oxide and a portion of the microcrystalline cellulose, e.g. 2.000 kg, which is screened through an 0.8 mm mesh screen manually before transfer to the main mixture may be performed.
  • the resulting bilayer tablets display virtually the same physical characteristics as described in example 2, except for the color.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Insulating Materials (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Lubricants (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

A bilayer pharmaceutical tablet comprises a first layer formulated for immediate release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix which contains telmisartan in substantially amorphous form, and a second layer formulated for immediate release of a diuretic like hydrochlorothiazide from a fast disintegrating tablet matrix. A method of producing the bilayer tablet is also disclosed.

Description

BILAYER PHARMACEUTICAL TABLET COMPRISING TELMISARTAN AND A DIURETIC AND PREPARATION THEREOF
Field of invention
The present invention relates to a bilayer pharmaceutical tablet formulation comprising the angiotensin II receptor antagonist telmisartan in combination with a diuretic such as hydrochlorothiazide (HCTZ). The present invention also provides a method of producing said bilayer tablet.
Background of the invention
INN Telmisartan is an angiotensin II receptor antagonist developed for the treatment of hypertension and other medical indications as disclosed in EP-A-502314.
Its chemical name is 4'-[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)- benzimidazol-1-ylmethyl]-biphenyl-2-carboxylic acid having the following structure:
Figure imgf000002_0001
Telmisartan is generally manufactured and supplied in the free acid form. It is characterized by its very poor solubility in aqueous systems at the physiological pH range of the gastro-intestinal tract of between pH 1 to 7. As disclosed in WO 00/43370, crystalline telmisartan exists in two polymorphic forms having different melting points. Under the influence of heat and humidity, the lower melting polymorph B transforms irreversibly into the higher melting polymorph A. Hydrochlorothiazide (HCTZ) is a thiazide diuretic which is orally administered in the treatment of edema and hypertension.
The chemical name of HCTZ is 6-chloro-3,4-dihydro-2H-1 ,2,4-benzothiadiazine- 7-sulfonamide-1 ,1 -dioxide having the following structure
Figure imgf000003_0001
Objects of the invention
Combination therapy of telmisartan with a diuretic like HCTZ is expected to show synergistic therapeutic efficacy in the treatment of hypertension.
It was therefore an object of the present invention to provide a fixed dose combination drug comprising telmisartan and a diuretic such as HCTC, said combination drug displaying the required fast dissolution and immediate drug release profile combined with adequate stability.
Generally, a fixed-dose combination of drugs intended for immediate release is prepared by either making a powder mixture or a co-granulate of the two active ingredients with the necessary excipients, normally keeping the basic formulation of the corresponding mono-drug preparation and simply adding the second drug component.
With a combination of telmisartan and HCTZ, this approach was not feasible due to the incompatibility of HCTZ with basic compounds such as, e.g., meglumine (N- methyl-D-glucamine) which is a component of conventional telmisartan formulations, and the reduced dissolution rate of HCTZ from a dissolving matrix as compared with dissolution from a disintegrating tablet.
Several galenical approaches to overcome the incompatibility problem have been investigated. A classical approach is to coat the HCTZ particles in a fluidized-bed granulator with a polymer solution containing water soluble polymers . like hydroxypropylcellulose, hydroxypropylmethylcellulose or polyvinylpyrrolidone, thereby reducing the contact surface area of the HCTZ particles with the telmisartan formulation during mixing and compressing. Yet, by these means it was not possible to reduce the contact area of HCTZ with the telmisartan formulation in a compressed tablet to a degree sufficient to achieve the desired prolonged shelf life.
Furthermore, the dissolution rate of HCTZ from tablets comprising coated HCTZ in a telmisartan formulation was further reduced due to the gel-forming properties of the polymer.
Another approach was to produce separate film-coated tablets for telmisartan and HCTZ in such a size and shape that these could be filled into a capsule. By dividing the doses into two to four single small tablets for telmisartan and into one or two small tablets for HCTZ, a capsule of size 1 to 0 long could be filled. Yet, with this approach the drug dissolution rate of telmisartan was reduced compared to the single entities due to a lag-time effect of the large capsule shells. Furthermore, with regard to patients' compliance a zero long capsule is not deemed reliable.
Summary of the invention
In accordance with the present invention, is has now been found that the above- described problems associated with conventional approaches in the preparation of a fixed dose combination drug comprising telmisartan and a diuretic could be overcome by means of a bilayer pharmaceutical tablet comprising a first layer containing telmisartan in substantially amorphous form in a dissolving tablet matrix, and a second layer containing a diuretic in a disintregrating tablet matrix.
The bilayer tablet according to the present invention provides a largely pH- independent dissolution of the poorly water-soluble telmisartan, thereby facilitating dissolution of the drug at a physiological pH level, and also provides for immediate release of the diuretic from the fast disintegrating matrix. At the same time, the bilayer tablet structure overcomes the stability problem caused by the incompatibility of diuretics like HCTZ with basic constitutents of the telmisartan formulation.
In a further aspect, the present invention relates to an improvement in bilayer tableting technology and provides a method of producing a bilayer pharmaceutical tablet comprising the steps of: (i) providing a first tablet layer composition by a) preparing an aqueous solution of telmisartan, at least one basic agent and, optionally, a solubilizer and/or a crystallization retarder; b) spray-drying said aqueous solution to obtain a spray-dried granulate; c) mixing said spray-dried granulate with a water-soluble diluent to obtain a premix; d) mixing said premix with a lubricant to obtain a final blend for the first tablet layer; e) optionally, adding other excipients and/or adjuvants in any of steps a) to d); (ii) providing a second tablet layer composition by f) mixing and/or granulating a diuretic with the constituents of a disintegrating tablet matrix and, optionally, further excipients and/or adjuvants; g) admixing a lubricant to obtain a final blend for the second tablet layer; (iii) introducing the first or the second tablet layer composition in a tablet press; (iv) compressing said tablet layer composition to form a tablet layer;
(v) introducing the other tablet layer composition into the tablet press; and (vi) compressing both tablet layer compositions to form a bilayer tablet.
Definitions
As used herein, the term "substantially amorphous" refers to a product comprising amorphous constituents in a proportion of at least 90%, preferably at least 95%, as determined by X-ray powder diffraction measurement.
The term "dissolving tablet matrix" refers to a pharmaceutical tablet base formulation having immediate release (fast dissolution) characteristics that readily dissolves in a physiological aqueous medium.
The term "diuretic" refers to thiazide and thiazide-analogue diuretics like hydrochlorothiazide (HCTZ), clopamide, xipamide or chlorotalidone, and any other diuretic suitable in the treatment of hypertension like, e.g., furosemide and piretanide, and combinations thereof with amiloride and triamteren. The term "disintegrating tablet matrix" refers to a pharmaceutical tablet base formulation having immediate release characteristics that readily swells and disintegrates in a physiological aqueous medium.
Description of the preferred embodiments
The bilayer tablet according to the present invention comprises a first layer containing telmisartan in substantially amorphous form in a dissolving tablet matrix, and a second layer containing a diuretic in a disintregrating tablet matrix.
The active ingredient telmisartan is generally supplied in its free acid form, although pharmaceutically acceptable salts may also be used. Since during subsequent processing telmisartan is normally dissolved and transformed into a substantially amorphous form, its initial crystal morphology and particle size are of little importance for the physical and biopharmaceutical properties of the bilayer tablet formulation obtained. It is however preferred to remove agglomerates from the starting material, e.g. by sieving, in order to facilitate wetting and dissolution during further processing.
Substantially amorphous telmisartan may be produced by any suitable method known to those skilled in the art, for instance, by freeze drying of aqueous solutions, coating of carrier particles in a fluidized bed, and solvent deposition on sugar pellets or other carriers. Preferably, however, the substantially amorphous telmisartan is prepared by the specific spray-drying method described hereinafter.
The other active ingredient, i.e. the diuretic, is usually employed as a fine- crystalline powder, optionally in fine-milled, peg-milled or micronized form. For instance, the particle size distribution of hydrochlorothiazide, as determined by the method of laser light scattering in a dry dispersion system (Sympatec Helos/Rodos, focal length 100 mm) is preferably as follows: io < 20 μm, preferably 2 to 10 μm dso 5 to 50 μm, preferably 10 to 30 μm dgo 20 to 100 μm, preferably 40 to 80 μm The bilayer tablet according to the present invention generally contains 10 to 160 mg, preferably 20 to 80 mg, of telmisartan and 6.25 to 50 mg, preferably 12.5 to 25 mg, of diuretic. Presently preferred forms are bilayer tablets comprising 40/12.5 mg, 80/12.5 mg and 80/25 mg of telmisartan and HCTZ, respectively.
The first tablet layer contains telmisartan in substantially amorphous form dispersed in a dissolving tablet matrix having immediate release (fast dissolution) characteristics. The dissolving tablet matrix may have acidic, neutral or basic properties, although a basic tablet matrix is preferred.
In such preferred embodiments, the dissolving matrix comprises a basic agent, a water-soluble diluent and, optionally, other excipients and adjuvants.
Specific examples of suitable basic agents are alkali metal hydroxides such as NaOH and KOH; basic amino acids such as arginine and lysine; and meglumine (N- methyl-D-glucamine), NaOH and meglumine being preferred.
Specific examples of suitable water-soluble diluents are carbohydrates such as monosaccharides like glucose; oligosaccharides like sucrose, anhydrous lactose and lactose monohydrate; and sugar alcohols like sorbitol, mannitol, dulcitol, ribitol and xylitol. Sorbitol is a preferred diluent.
The other excipients and/or adjuvants are, for instance, selected from binders, carriers, fillers, lubricants, flow control agents, crystallization retarders, solubilizers, coloring agents, pH control agents, surfactants and emulsifiers, specific examples of which are given below in connection with the second tablet layer composition. The excipients and/or adjuvants for the first tablet layer composition are preferably chosen such that a non-acidic, fast dissolving tablet matrix is obtained.
The first tablet layer composition generally comprises 3 to 50 wt.%, preferably 5 to 35 wt.%, of active ingredient; 0.25 to 20 wt.%, preferably 0.40 to 15 wt.%, of basic agent; and 30 to 95 wt.%, preferably 60 to 80 wt.% of water-soluble diluent.
Other (optional) constituents may, for instance, be chosen from one or more of the following excipients and/or adjuvants in the amounts indicated:
10 to 30 wt.%, preferably 15 to 25 wt.%, of binders, carriers and fillers, thereby replacing the water-soluble diluent;
0.1 to 5 wt.%, preferably 0.5 to 3 wt.%, of lubricants; 0.1 to 5 wt.%, preferably 0.3 to 2 wt.%, of flow control agents;
1 to 10 wt.%, preferably 2 to 8 wt.%, of crystallization retarders;
1 to 10 wt.%, preferably 2 to 8 wt.%, of solubilizers;
0.05 to 1.5 wt.%, preferably 0.1 to 0.8 wt.%, of coloring agents;
0.5 to 10 wt.%, preferably 2 to 8 wt.%, of pH control agents;
0.01 to 5 wt.%, preferably 0.05 to 1 wt.%, of surfactants and emulsifiers.
The second tablet layer composition contains a diuretic in a fast disintegrating tablet matrix. In a preferred embodiment, the disintegrating tablet matrix comprises a filler, a binder, a disintegrant and, optionally, other excipients and adjuvants.
The filler is preferably selected from anhydrous lactose, spray-dried lactose and lactose monohydrate.
The binder is selected from the group of dry binders and/or the group of wet granulation binders, depending on the manufacturing process chosen for the second tablet layer. Suitable dry binders are, e.g., cellulose powder and microcrystalline cellulose. Specific examples of wet granulation binders are corn starch, polyvinyl pyrrolidone (Povidon), vinylpyrrolidone-vinylacetate copolymer (Copovidone) and cellulose derivatives like hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose.
Suitable disintegrants are, e.g., sodium starch glycolate, Crospovidon, Croscarmellose, sodium carboxymethylcellulose and dried corn starch, sodium starch glycoiate being preferred.
The other excipients and adjuvants, if used, are preferably selected from diluents and carriers such as cellulose powder, microcrystalline cellulose, cellulose derivatives like hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose, dibasic calcium phosphate, corn starch, pregelatinized starch, polyvinyl pyrrolidone (Povidone) etc.; lubricants such as stearic acid, magnesium stearate, sodium stearylfumarate, glycerol tribehenate, etc.; flow control agents such as colloidal silica, talc, etc.; crystallization retarders such as Povidone, etc.; solubilizers such as Pluronic, Povidone, etc.; coloring agents, including dyes and pigments such as Iron Oxide Red or Yellow, titanium dioxide, talc, etc.; pH control agents such as citric acid, tartaric acid, fumaric acid, sodium citrate, dibasic calcium phosphate, dibasic 02 00395
8
sodium phosphate, etc.; surfactants and emulsifiers such as Pluronic, polyethylene glycols,. sodium carboxymethyl cellulose, polyethoxylated and hydrogenated castor oil, etc.; and mixtures of two or more of these excipients and/or adjuvants.
The second tablet layer composition generally comprises 1.5 to 35 wt.%, preferably 2 to 15 wt.%, of active ingredient; 25 to 75 wt.%, preferably 35 to 65 wt.%, of filler; 10 to 40 wt.%, preferably 15 to 35 wt.%, of dry binder; 0.5 to 5 wt.%, preferably 1 to 4 wt.%, of wet granulation binder; and 1 to 10 wt.%, preferably 2 to 8 wt.%, of disintegrant. The other excipients and adjuvants are generally employed in the same amount as in the first tablet layer composition.
For preparing the bilayer tablet according to the present invention, the first and second tablet layer compositions may be compressed in the usual manner in a bilayer tablet press, e.g. a high-speed rotary press in a bilayer tableting mode. However, care should be taken not to employ an excessive compression force for the first tablet layer. Preferably, the ratio of the compression force applied during compression of the first tablet layer to the compression force applied during compression of both the first and second tablet layers is in the range of from 1 :10 to 1:2. For instance, the first tablet layer may be compressed at moderate force of 4 to 8 kN, whereas the main compression of first plus second layer is performed at a force of 10 to 20 kN.
During bilayer tablet compression adequate bond formation between the two layers is achieved by virtue of distance attraction forces (intermolecular forces) and mechanical interlocking between the particles.
The bilayer tablets obtained release the active ingredients rapidly and in a largely pH-independent fashion, with complete release occurring within less than 60 min and release of the major fraction occurring within less than 15 min. The dissolution/- disintegration kinetics of the bilayer tablet may be controlled in different ways. For instance, both layers may dissolve/disintegrate simultaneously. Preferably, however, the second tablet layer containing the diuretic disintegrates first whereas the first tablet layer containing telmisartan dissolves in parallel or subsequently.
In accordance with the present invention, a substantially increased dissolution rate of the active ingredients and, in particular, of telmisartan is achieved. Normally, at least 70% and typically at least 90% of the drug load are dissolved after 30 min. The bilayer tablets of the present invention tend to be slightly hygroscopic and are therefore preferably packaged using a moisture-proof packaging material such as aluminium foil blister packs, or polypropylene tubes and HDPE bottles which preferably contain a desiccant.
For optimum dissolution/disintegration and drug release properties, a specific method of producing the bilayer tablet according to the present invention has been developed which method comprises (i) providing a first tablet layer composition by a) preparing an aqueous solution of telmisartan, at least one basic agent and, optionally, a solubilizer and/or a crystallization retarder; b) spray-drying said aqueous solution to obtain a spray-dried granulate; c) mixing said spray-dried granulate with a water-soluble diluent to obtain a premix; d) mixing said premix with a lubricant to obtain a final blend for the first layer; e) optionally, adding other excipients and/or adjuvants in any of steps a) to d); (ii) providing a second tablet layer composition by f) mixing and /or granulating a diuretic with the constituents of a disintegrating tablet matrix and, optionally, further excipients and/or adjuvants; g) admixing a lubricant to obtain a final blend for the second tablet layer; (iii) introducing the first or the second tablet layer composition into a tablet press; (iv) compressing said tablet layer composition to form a tablet layer;
(v) introducing the other tablet layer composition into the tablet press; and (vi) compressing both tablet layer compositions to form a bilayer tablet.
In a preferred embodiment of this method, an aqueous alkaline solution of telmisartan is prepared by dissolving the active ingredient in purified water with the help of one or more basic agents like sodium hydroxide and meglumine. Optionally, a solubilizer and/or a recrystallization retarder may be added. The dry matter content of the starting aqueous solution is generally 10 to 40 wt.%, preferably 20 to 30 wt.%.
The aqueous solution is then spray-dried at room temperature or preferably at increased temperatures of, for instance, between 50 and 100°C in a co-current or countercurrent spray-drier at a spray pressure of, for instance, 1 to 4 bar. Generally speaking, the spray-drying conditions are preferably chosen in such a manner that a spray-dried granulate having a residual humidity of < 5 wt.%, preferably < 3.5 wt.%, is obtained in the separation cyclone. To that end, the outlet air temperature of the spray- drier is preferably kept at a value of between about 80 and 90°C while the other process parameters such as spray pressure, spraying rate, inlet air temperature, etc. are adjusted accordingly.
The spray-dried granulate obtained is preferably a fine powder having the following particle size distribution:
dio < 20 μm, preferably < 10 μm dδo < 80 μm, preferably 20 to 55 μm dgo < 350 μm, preferably 50 to 150 μm
After spray-drying, the active ingredient (telmisartan) as well as the excipients contained in the spray-dried granulate are in a substantially amorphous state with no crystallinity being detectable. From a physical point of view, the spray-dried granulate is a solidified solution or glass having a glass transition temperature Tg of preferably > 50°C, more preferably > 80°C.
Based on 100 parts by weight of active ingredient (telmisartan), the spray-dried granulate preferably contains 5 to 200 parts by weight of basic agent and, optionally, solubilizer and/or crystallization retarder.
The water-soluble diluent is generally employed in an amount of 30 to 95 wt.%, preferably 60 to 80 wt.%, based on the weight of the first tablet layer composition.
The lubricant is generally added to the premix in an amount of 0.1 to 5 wt.%, preferably 0.3 to 2 wt.%, based on the weight of the first tablet layer composition.
Mixing is carried out in two stages, i.e. in a first mixing step the spray-dried granulate and the diluent are admixed using , e.g., a high-shear mixer or a free-fall blender, and in a second mixing step the lubricant is blended with the premix, preferably also under conditions of high shear. The method of the invention is however not limited to these mixing procedures and, generally, alternative mixing procedures may be employed in steps c), d), and also in the subsequent steps f) and g), such as, e.g., container mixing with intermediate screening. For direct compression, the second tablet layer composition may be prepared by dry-mixing the constituent components, e.g. by means of a high-intensity mixer or a free-fall blender. Alternatively and preferably, the second tablet layer composition is prepared using a wet granulation technique wherein an aqueous solution of a wet granulation binder is added to a premix and subsequently the wet granulate obtained is dried, e.g. in a fluidized-bed dryer or drying chamber. The dried mixture is screened and then a lubricant is admixed, e.g. using a tumbling mixer or free-fall blender, whereafter the composition is ready for compression.
For production of the bilayer tablet according to the present invention, the first and second tablet layer compositions are compressed in a bilayer tablet press, e.g. a rotary press in the bilayer tableting mode, in the manner described above. In order to avoid any cross-contamination between the first and second tablet layers (which could lead to decomposition of HTCZ), any granulate residues have to be carefully removed during tableting by intense suction of the die table within the tableting chamber.
In order to further illustrate the present invention, the following non-limiting examples are given.
Example 1
Figure imgf000012_0001
Manufacturing:
1. Spray solution
225.000 kg of purified water are measured into a suitable stainless steel vessel at a temperature of between 20-40°C. In sequence, 3.780 of kg sodium hydroxide, 45.000 kg of telmisartan (mixture of polymorph A and B), 13.500 kg of Povidone K 25 and 13.500 kg of meglumine are dissolved in the purified water under intensive stirring until a virtually clear, slightly yellowish, alkaline solution is obtained.
2. Sprav drying
The solution is sprayed into a suitable spray dryer, e.g. a Niro P 6.3 equipped with Schlick atomizing nozzles of 1.0 mm diameter, with a flow-through heating coil connected upstream of the dryer, and dried to give a white to off-white fine granulate. The spray mode is counter-current at a spray-pressure of about 3 bar, an inlet air temperature of about 125°C and a spray rate of about 11 kg/h, thus resulting in an outlet air temperature of about 85°C. The temperature of the flow through heating coil water bath is set at a temperature of about 80°C.
3. Protective Screening
The dry granulate powder is screened through a screen of 0.5 mm mesh size, e.g. using a Vibra Sieve machine.
The resulting amorphous telmisartan spray-dried granulate may be further processed to telmisartan mono-tablets or the first layer of the said bilayer tablet composition. Example 2
Figure imgf000014_0001
200 mg in SD granulate, 64 mg in granulation liquid of HCTZ granulate
Manufacturing:
1. Final blend A
168.640 kg of sorbitol are mixed with 67.360 kg of telmisartan spray dried granulate in a suitable high shear mixer, e.g. Diosna P 600, for 4 minutes using both impeller and chopper. Next 4.0 kg of magnesium stearate are added to the resulting pre-mix and admixed in the high shear mixer for further 30 seconds. 0395
14
Final blend B
9.000 kg of purified water of about 70°C are transfered to a suitable mixing vessel, 6.000 kg of maize starch, dried at 45°C, are suspended in the water. This suspension is stirred into 55.000 kg of purified water of about 90°C using e.g. an Ekato stirrer.
Next, 112.170 kg of lactose monohydrate, 12.500 kg of hydrochlorothiazide, 64.000 kg of microcrystalline cellulose (Avicel PH 101), 0.330 kg of red iron oxide and 4.000 kg of sodium starch glycolate are mixed in a suitable high shear granulator, e.g. Diosna P 600, until homogeneous, and moistened with 70.000 kg of the above-prepared aqueous granulating liquid.
Process parameters for wet granulation:
Figure imgf000015_0001
After moistening, the resulting wet granulate is dried in a suitable fluid bed dryer, e.g. Glatt WSG 120 at an inlet air temperature of 100°C, an inlet air flow of 2000-3000 m3/h until a product temperature of about 55°C is reached.
The dry.granulate is screened to reduce the particle size using a suitable screening machine, e.g. a Comil screen machine equipped with a rasp screen of 2 mm mesh size. Finally 1.000 kg of prescreened magnesium stearate are admixed to the screened granulate material and mixed in a suitable tumbling mixer, e.g. a Lermer rotating spike mixer, for 100 revolutions at a speed of 8-10 rpm. 3. Bilayer tablet compression
Using a suitable rotary tablet press, 240 kg of the final blend (A) and 200 kg of the final blend (B) are compressed into bilayer tablets. The target weight for the first layer is 240 mg, the target weight for the second layer is 200 mg.
Process parameters for tableting:
Figure imgf000016_0001
As a rule, the tablet hardness is adjusted by variation of the main compression force of the second layer.
The resulting bilayer tablets have the following characteristics:
Figure imgf000016_0002
Example 3
Figure imgf000017_0001
Manufacturing:
Manufacturing is carried out as in Example 2. Instead of the wet granulation process described in Example 2, the second layer composition is manufactured by dry mixing of (09) to (13) in a suitable free fall blender, e.g. a i m3 container mixer, for 200 revolutions at a speed of 10 rpm. Then, (08) is admixed to the main mixture for further 50 revolutions in the container mixer. In order to achieve a homogenous distribution of the color pigment, an additional premix with yellow iron oxide and a portion of the microcrystalline cellulose, e.g. 2.000 kg, which is screened through an 0.8 mm mesh screen manually before transfer to the main mixture, may be performed. The resulting bilayer tablets display virtually the same physical characteristics as described in example 2, except for the color. Example 4
Composition of Telmisartan/Hydrochlorothiazide Bilayer Tablets (mg per tablet):
Figure imgf000018_0001
*Does not appear in final product

Claims

C L A I M S
1. A bilayer pharmaceutical tablet comprising a first layer containing telmisartan in substantially amorphous form in a dissolving tablet matrix, and a second layer containing a diuretic in a disintegrating tablet matrix.
2. A bilayer pharmaceutical tablet as claimed in claim 1 wherein the diuretic is selected from at least one of hydrochlorothiazide, furosemide, chlorotalidone, piretanide and amiloride.
3. A bilayer pharmaceutical tablet as claimed in claim 2 wherein the diuretic is hydrochlorothiazide.
4. A bilayer pharmaceutical tablet as claimed in any one of claims 1-3 wherein the dissolving tablet matrix has immediate release characteristics.
5. A bilayer pharmaceutical tablet as claimed in any one of claims 1-4 wherein the dissolving tablet matrix comprises a basic agent, a water-soluble diluent and, optionally, other excipients and adjuvants.
6. A bilayer pharmaceutical tablet as claimed in claim 5 where the basic agent is selected from alkali metal hydroxides, basic amino acids and meglumine.
7. A bilayer pharmaceutical tablet as claimed in claims 5 or 6 wherein the water- soluble diluent is selected from carbohydrates such as monosaccharides like glucose; oligosaccharides like sucrose and lactose; and sugar alcohols like sorbitol, mannitol, dulcitol, ribitol and xylitol.
8. A bilayer pharmaceutical tablet as claimed in any one of claims 5-7 wherein the other excipients and adjuvants are selected from binders, carriers, fillers, lubricants, flow control agents, crystallization retarders, solubilizers, coloring agents, pH control agents, surfactants and emulsifiers.
9. A bilayer pharmaceutical tablet as claimed in any one of claims 1-8 wherein the first tablet layer has been produced by spray-drying an aqueous solution comprising telmisartan and a basic agent to obtain a spray-dried granulate, mixing said spray-dried granulate with a water-soluble diluent to obtain a premix, mixing said premix with a lubricant to obtain a final blend and compressing the final blend to form the first tablet layer.
10. A bilayer pharmaceutical tablet as claimed in any one of claims 1-10 wherein the disintegrating tablet matrix comprises a filler, a binder, a disintegrant and, optionally, other excipients and adjuvants.
11. A bilayer pharmaceutical tablet as claimed in claim 10 wherein the other excipients and adjuvants are selected from carriers, diluents, lubricants, flow control agents, solubilizers, coloring agents, pH control agents, surfactants and emulsifiers.
12. A bilayer pharmaceutical tablet as claimed in any one of claims 1-11 containing 10 to 160 mg, preferably 20 to 80 mg, of telmisartan and 6.25 to 50 mg, preferably 12.5 to 25 mg, of diuretic.
13. A bilayer pharmaceutical tablet as claimed in any one of claims 1-12 packaged in a moisture proof packaging material such as aluminium foil blister packs, or polypropylene tubes and HDPE bottles.
14. A method of producing a bilayer pharmaceutical tablet comprising the steps of: (i) providing a first tablet layer composition by a) preparing an aqueous solution of telmisartan, at least one basic agent and, optionally, a solubilizer and/or a crystallization retarder; b) spray-drying said aqueous solution to obtain a spray-dried granulate; c) mixing said spray-dried granulate with a water-soluble diluent to obtain a premix; d) mixing said premix with a lubricant to obtain a final blend for the first tablet layer; e) optionally, adding other excipients and/or adjuvants in any of steps a) to d); (ii) providing a second tablet layer composition by f) mixing and/or granulating a diuretic with the constituents of a disintegrating tablet matrix and, optionally, further excipients and/or adjuvants; g) admixing a lubricant to obtain a final blend for the second tablet layer;
(iii) introducing the first or the second tablet layer composition into a tablet press; (iv) compressing said tablet layer composition to form a tablet layer; (v) introducing the other tablet layer composition into the tablet press; and (vi) compressing both tablet layer compositions to form a bilayer tablet.
15. A method as claimed in claim 14 wherein spray-drying in step b) is carried out under conditions so as to obtain a spray-dried granulate having a residual humidity of < 5 wt.%, preferably < 3.5 wt.%.
16. A method as claimed in claims 14 or 15 wherein spray-drying in step b) is carried out at an outlet air temperature of the spray-drier of between about 80 and 90°C.
17. A method as claimed in any one of claims 14-16 wherein mixing in any of steps c), d), f) and g) is carried out in a high shear mixer or a free-fall blender.
18. A method as claimed in any one of claims 14-17 wherein mixing in step f) is carried out under conditions of dry-mixing or, preferably, under wet granulation conditions.
19. A method as claimed in any one of claims 14-18 wherein the ratio of the compression force applied during compression of the first tablet layer to the compression force applied during compression of both the first and second tablet layers is in the range of from 1 :10 to 1 :2.
PCT/EP2002/000395 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof WO2003059327A1 (en)

Priority Applications (55)

Application Number Priority Date Filing Date Title
AU2002242676A AU2002242676B2 (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
EP10179142A EP2260833B1 (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic
SK290-2004A SK288439B6 (en) 2002-01-16 2002-01-16 Method of producing bilayer pharmaceutical tablet, and bilayer pharmaceutical tablet
CA2651604A CA2651604C (en) 2002-01-16 2002-01-16 Method for preparation of substantially amorphous telmisartan
DK02708290.8T DK1467712T4 (en) 2002-01-16 2002-01-16 A process for preparing a two-layer pharmaceutical tablet comprising telmisartan and hydrochlorothiazide
YU61104A RS52012B (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
PT101791424T PT2260833E (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic
MEP-2008-424A ME02761B (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
IL16275402A IL162754A0 (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartane and a diuretic and preparation thereof
KR1020087003317A KR100876302B1 (en) 2002-01-16 2002-01-16 A method for the preparation of substantially amorphous telmisartan
CA002472392A CA2472392C (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
DK07115060.1T DK1854454T3 (en) 2002-01-16 2002-01-16 Process for the preparation of amorphous telmisartan
CZ20040939A CZ303145B6 (en) 2002-01-16 2002-01-16 Process for preparing bilayer pharmaceutical tablet containing telmisartan and hydrochlorothiazide
JP2003559490A JP4181503B2 (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet containing telmisartan and diuretic and method for producing the same
EA200400879A EA007614B1 (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet and method for producing thereof
UA20040806794A UA78273C2 (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet containing telmisartan and hydrochlorothiazide and method for producing thereof
DE60224096T DE60224096T3 (en) 2002-01-16 2002-01-16 METHOD FOR PRODUCING A TWO-LAYER PHARMACEUTICAL TABLET CONTAINING TELMISARTAN AND HYDROCHLOROTHIAZIDE
KR1020047011113A KR100851770B1 (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
NO20171988A NO345891B1 (en) 2002-01-16 2002-01-16 Two-tier pharmaceutical tablet for use in a method of treating hypertension comprising telmisartan and a diuretic
HU0501086A HU229941B1 (en) 2002-01-16 2002-01-16 Preparation of bilayer pharmaceutical tablet comprising telmisartan and a hydrochlorothiazide
CNA2008102144454A CN101352421A (en) 2002-01-16 2002-01-16 Method for preparing basically non-crystalline type telmisartan
NZ534502A NZ534502A (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising the angiotensin II receptor antagonist telmisartan and a diuretic
EP07115060.1A EP1854454B1 (en) 2002-01-16 2002-01-16 Method for the preparation of amorphous telmisartan
CNB028271823A CN100571695C (en) 2002-01-16 2002-01-16 Contain layer tablets of telmisartan and diuretic and preparation method thereof
EA200601917A EA012329B1 (en) 2002-01-16 2002-01-16 Method of producing substantially amorphous telmisartan
PT02708290T PT1467712E (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and hydrochlorothiazide
BR0215514-1A BR0215514A (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
MXPA04006997A MXPA04006997A (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof.
SI200230664T SI1467712T2 (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and hydrochlorothiazide
AT02708290T ATE380547T1 (en) 2002-01-16 2002-01-16 DOUBLE-LAYER PHARMACEUTICAL TABLET CONTAINING TELMISARTAN AND HYDROCHLOROTHIAZIDE
PCT/EP2002/000395 WO2003059327A1 (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
ES02708290T ES2298351T5 (en) 2002-01-16 2002-01-16 METHOD FOR PRODUCING A TWO-LAYER PHARMACEUTICAL TABLET THAT INCLUDES TELMISARTAN AND HYDROCLOROTIAZIDA.
EP02708290A EP1467712B2 (en) 2002-01-16 2002-01-16 Method of producing a bilayer pharmaceutical tablet comprising telmisartan and hydrochlorothiazide
PT71150601T PT1854454E (en) 2002-01-16 2002-01-16 Method for the preparation of amorphous telmisartan
ES07115060.1T ES2445041T3 (en) 2002-01-16 2002-01-16 Method for the preparation of amorphous telmisartan
ES10179142T ES2400138T3 (en) 2002-01-16 2002-01-16 Two-layer pharmaceutical tablet comprising telmisartan and a diuretic
DK10179142.4T DK2260833T3 (en) 2002-01-16 2002-01-16 Two-layer pharmaceutical tablet comprising telmisartan and a diuretic
IL162754A IL162754A (en) 2002-01-16 2004-06-28 Method for producing a bilayer pharmaceutical tablet comprising telmisartan and a diuretic
BG108781A BG66524B1 (en) 2002-01-16 2004-06-30 Method for preparing a bilayer pharmaceutical tablet comprising telmisartan and hydrochlorothiazide
US10/892,425 US20050089575A1 (en) 2002-01-16 2004-07-15 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
HR20040649 HRP20040649B1 (en) 2002-01-16 2004-07-15 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
NO20043344A NO342634B1 (en) 2002-01-16 2004-08-11 Process for the preparation of a two-layer pharmaceutical tablet
HK05106429.3A HK1073785A1 (en) 2002-01-16 2005-07-27 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
CY20081100247T CY1107226T1 (en) 2002-01-16 2008-03-04 TWO-LAYER PHARMACEUTICAL DISC, INCLUDING TELEMISARTAN AND HYDROCHLOROTHIAZIDE
JP2008180150A JP4929241B2 (en) 2002-01-16 2008-07-10 Preparation of telmisartan, which is substantially amorphous
AU2008203182A AU2008203182B2 (en) 2002-01-16 2008-07-17 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
IL194933A IL194933A (en) 2002-01-16 2008-10-27 Method for the preparation of amorphous telmisartan
US12/464,957 US20090227802A1 (en) 2002-01-16 2009-05-13 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
IL219481A IL219481A (en) 2002-01-16 2012-04-30 Bilayer pharmaceutical tablet for use in the treatment of hypertension comprising telmisartane and a thiazide diuretic
CY20131100140T CY1114929T1 (en) 2002-01-16 2013-02-15 TWO-LAYER MEDICINAL DISC WHICH INCLUDES TELMISSARTAN AND A DIRECTIVE
US13/947,429 US20130309307A1 (en) 2002-01-16 2013-07-22 Bilayer Pharmaceutical Tablet Comprising Telmisartan and a Diuretic and Preparation Thereof
CY20141100062T CY1114890T1 (en) 2002-01-16 2014-01-24 METHOD FOR PREPARING AMPORATED TELMISARTAN
NO20140821A NO336167B1 (en) 2002-01-16 2014-06-27 Process for the preparation of telmisartan in at least 90% amorphous form.
BG112153A BG66588B1 (en) 2002-01-16 2015-11-19 Method for preparing amorphous telmisartan
BG112220A BG67075B1 (en) 2002-01-16 2016-02-25 Bylayer pharmaceutical tablet containing telmisartan and a diuretic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2002/000395 WO2003059327A1 (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/892,425 Continuation US20050089575A1 (en) 2002-01-16 2004-07-15 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof

Publications (1)

Publication Number Publication Date
WO2003059327A1 true WO2003059327A1 (en) 2003-07-24

Family

ID=8164784

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/000395 WO2003059327A1 (en) 2002-01-16 2002-01-16 Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof

Country Status (30)

Country Link
US (3) US20050089575A1 (en)
EP (3) EP1854454B1 (en)
JP (2) JP4181503B2 (en)
KR (2) KR100876302B1 (en)
CN (2) CN101352421A (en)
AT (1) ATE380547T1 (en)
AU (2) AU2002242676B2 (en)
BG (3) BG66524B1 (en)
BR (1) BR0215514A (en)
CA (2) CA2472392C (en)
CY (3) CY1107226T1 (en)
CZ (1) CZ303145B6 (en)
DE (1) DE60224096T3 (en)
DK (3) DK2260833T3 (en)
EA (2) EA007614B1 (en)
ES (3) ES2298351T5 (en)
HK (1) HK1073785A1 (en)
HR (1) HRP20040649B1 (en)
HU (1) HU229941B1 (en)
IL (4) IL162754A0 (en)
ME (1) ME02761B (en)
MX (1) MXPA04006997A (en)
NO (3) NO345891B1 (en)
NZ (1) NZ534502A (en)
PT (3) PT2260833E (en)
RS (1) RS52012B (en)
SI (1) SI1467712T2 (en)
SK (1) SK288439B6 (en)
UA (1) UA78273C2 (en)
WO (1) WO2003059327A1 (en)

Cited By (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004028505A1 (en) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Solid pharmaceutical formulations comprising telmisartan
WO2005014043A1 (en) * 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
WO2005082329A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
WO2006048208A1 (en) * 2004-11-05 2006-05-11 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and amlodipine
WO2006063737A1 (en) * 2004-12-17 2006-06-22 Boehringer Ingelheim International Gmbh Combination therapy comprising telmisartan and hydrochlorothiazide
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
WO2007061415A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of telmisartan
WO2007060170A2 (en) * 2005-11-24 2007-05-31 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1797872A1 (en) * 2005-11-22 2007-06-20 Teva Pharmaceutical Industries Ltd Telmisartan-containing pharmaceutical compositions for oral intake
EP1807400A2 (en) * 2004-11-03 2007-07-18 Teva Pharmaceutical Industries, Inc. Amorphous and polymorphic forms of telmisartan sodium
WO2007144175A2 (en) 2006-06-16 2007-12-21 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
WO2008044862A1 (en) * 2006-10-10 2008-04-17 Hanall Pharmaceutical Co., Ltd. Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
US7501448B2 (en) 2004-10-15 2009-03-10 Teva Pharmaceutical Industries, Ltd. Process for preparing telmisartan
EP2037893A2 (en) * 2006-06-27 2009-03-25 Novartis AG Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
WO2009115301A1 (en) * 2008-03-19 2009-09-24 Ratiopharm Gmbh Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
WO2010057449A2 (en) 2008-11-24 2010-05-27 Zentiva, K.S. A solid pharmaceutical composition with atorvastatin and telmisartan as the active substances
EP2203158A2 (en) 2007-10-30 2010-07-07 Dr. Reddy's Laboratories, Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
WO2010081824A2 (en) 2009-01-14 2010-07-22 Lek Pharmaceuticals D.D. Active coating of pharmaceutical dosage forms
WO2010075347A3 (en) * 2008-12-23 2010-08-19 Takeda Pharmaceutical Company Limited Treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
WO2010146187A2 (en) 2009-06-19 2010-12-23 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
US20110318411A1 (en) * 2010-06-24 2011-12-29 Luber Joseph R Multi-layered orally disintegrating tablet and the manufacture thereof
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
WO2013050339A1 (en) 2011-10-03 2013-04-11 Ems S/A Pharmaceutical compositions of antihypertensives
EP2612658A1 (en) 2012-01-05 2013-07-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
WO2014026261A1 (en) * 2012-08-17 2014-02-20 Hypermarcas S.A. Solid oral pharmaceutical preparation for preventing cerebrovascular and heart diseases, and tablet
US8784781B2 (en) 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
US8871271B2 (en) 2005-06-13 2014-10-28 Gilead Sciences, Inc. Method and composition for pharmaceutical product
US8956662B2 (en) 2006-06-01 2015-02-17 Msd Consumer Care, Inc. Phenylephrine pharmaceutical formulations and compositions for colonic absorption
US8968769B2 (en) 2007-10-31 2015-03-03 Mcneil-Ppc, Inc. Orally disintegrative dosage form
AU2011306063B2 (en) * 2010-09-22 2015-03-12 Mcneil-Ppc, Inc. Multi-layered orally disintegrating tablet and the manufacture thereof
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
US9018192B2 (en) 2005-06-13 2015-04-28 Bristol-Myers Squibb & Gilead Sciences, Inc. Unitary pharmaceutical dosage form
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
US9321791B2 (en) 2002-08-21 2016-04-26 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9415016B2 (en) 2008-04-03 2016-08-16 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9457036B2 (en) 2003-01-14 2016-10-04 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9493462B2 (en) 2006-05-04 2016-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US9499546B2 (en) 2004-11-05 2016-11-22 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
KR20170001921A (en) 2015-06-26 2017-01-05 대원제약주식회사 A pharmaceutical composition comprising telmisartan with increased stability and a preparation method thereof
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
KR20170012703A (en) 2015-07-22 2017-02-03 대원제약주식회사 A pharmaceutical composition comprising telmisartan and a preparation method thereof
US9603851B2 (en) 2010-05-05 2017-03-28 Boehringer Ingelheim International Gmbh Combination therapy
CN106749037A (en) * 2016-12-21 2017-05-31 山东大学 A kind of unformed Telmisartan glutaric acid eutectic and its preparation method and application
CN106749036A (en) * 2016-12-21 2017-05-31 山东大学 A kind of unformed Telmisartan pimelic acid eutectic and its preparation method and application
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
US9789066B2 (en) 2014-01-10 2017-10-17 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
WO2017207375A1 (en) 2016-05-30 2017-12-07 Boehringer Ingelheim International Gmbh Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
WO2018084627A3 (en) * 2016-11-03 2018-07-26 Hanmi Pharm. Co., Ltd. Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
US10080754B2 (en) 2006-05-04 2018-09-25 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
WO2023001880A1 (en) 2021-07-22 2023-01-26 Krka, D. D., Novo Mesto Bilayer tablet comprising telmisartan and indapamide
US20230111273A1 (en) * 2020-12-10 2023-04-13 Novitium Pharma LLC Hydrochlorothiazide compositions
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
US11911387B2 (en) 2010-11-15 2024-02-27 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854454B1 (en) * 2002-01-16 2013-11-06 Boehringer Ingelheim Pharma GmbH & Co. KG Method for the preparation of amorphous telmisartan
DE10319450A1 (en) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical formulation of telmisartan sodium salt
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
CN100370984C (en) * 2005-03-11 2008-02-27 浙江泰利森药业有限公司 Telmisartan dispersible tablet and its preparation method
GT200600371A (en) * 2005-08-17 2007-03-21 SOLID DOSE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD TO DO THE SAME
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
WO2007121188A2 (en) * 2006-04-10 2007-10-25 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
EP2497472A1 (en) 2006-05-16 2012-09-12 Knopp Neurosciences, Inc. Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of Parkinson's disease and their pharmaceutical compositions
ATE537826T1 (en) 2006-05-16 2012-01-15 Knopp Neurosciences Inc COMPOSITIONS OF R(+)- AND S(-)-PRAMIPEXOLE AND METHOD FOR THEIR USE
WO2008054121A1 (en) * 2006-10-30 2008-05-08 Hanall Pharmaceutical Company. Ltd Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2137171A4 (en) * 2007-03-14 2010-05-19 Knopp Neurosciences Inc Synthesis of chirally purified substituted benzothiazole diamines
US20080286344A1 (en) * 2007-05-16 2008-11-20 Olivia Darmuzey Solid form
US20090004248A1 (en) * 2007-06-29 2009-01-01 Frank Bunick Dual portion dosage lozenge form
WO2009135646A2 (en) * 2008-05-05 2009-11-12 Farmaprojects, Sa Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
CZ2008469A3 (en) * 2008-07-31 2009-10-29 Zentiva, A. S. Telmisartan tablets
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2010137855A2 (en) * 2009-05-27 2010-12-02 Dasan Medichem Co., Ltd. Multi-layer tablet comprising effervescent layer
JP2012529431A (en) * 2009-06-08 2012-11-22 メルク・シャープ・アンド・ドーム・コーポレーション Fixed dose tablets of thrombin receptor antagonist and clopidogrel
AU2010261509A1 (en) * 2009-06-19 2012-02-09 Nanoform Hungary Ltd. Nanoparticulate telmisartan compositions and process for the preparation thereof
JP2012530723A (en) * 2009-06-19 2012-12-06 ノップ ニューロサイエンシーズ、インク． Compositions and methods for treating amyotrophic lateral sclerosis
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
TR200906506A2 (en) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Solid dosage forms containing telmisartan.
CN101632678B (en) * 2009-09-01 2011-09-14 严洁 Losartan potassium hydrochlorothiazide composition and preparation method thereof
KR101010325B1 (en) * 2009-12-17 2011-01-25 현대약품 주식회사 Pharmaceutical composition comprising telmisartan and hydrochlorothiazide
EP2377521A1 (en) 2010-03-26 2011-10-19 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of telmisartan and diuretic combination
KR101248804B1 (en) * 2010-05-14 2013-03-29 한미사이언스 주식회사 BILAYERED PHARMACEUTICAL COMPOSITION OF HMG-CoA REDUCTASE INHIBITOR AND IRBESARTAN
CN102552161B (en) * 2010-12-28 2016-06-22 上海中西制药有限公司 The preparation method of a kind of pharmaceutical solid preparation and gained pharmaceutical solid preparation
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US20140377347A1 (en) * 2012-01-23 2014-12-25 Ranbaxy Laboratories Limited In-situ multilayered tablet technology
CN102885789A (en) * 2012-04-05 2013-01-23 常州制药厂有限公司 Preparation method of compound preparation for treating high blood pressure
KR101414873B1 (en) * 2012-06-28 2014-07-03 보령제약 주식회사 Pharmaceutical composition of Fimasartan and Hydrochlorothiazide
CN103040817A (en) * 2013-01-08 2013-04-17 施慧达药业集团(吉林)有限公司 Compound preparation for treating hypertension
WO2014119767A1 (en) 2013-01-31 2014-08-07 沢井製薬株式会社 Multilayer tablet containing telmisartan and hydrochlorothiazide
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
RS61539B1 (en) 2013-07-12 2021-04-29 Knopp Biosciences Llc Treating elevated levels of eosinophils and/or basophils
CA2921381A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
ES2813674T3 (en) 2013-08-13 2021-03-24 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
JP5871294B1 (en) * 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Immediate release oral tablets
CN109562074A (en) * 2016-08-11 2019-04-02 因特欧生物制药有限公司 Single-layer sheet compound formulation comprising Telmisartan
KR20200014049A (en) 2018-07-31 2020-02-10 일동제약(주) Pharmaceutical composition having storage stability for the treatment of hypertension and hyperlipidermia
CN110934848B (en) * 2019-12-20 2022-02-15 江西杏林白马药业股份有限公司 Telmisartan capsule and preparation method thereof
CN112263555B (en) * 2020-10-30 2023-03-24 重庆康刻尔制药股份有限公司 Telmisartan orally disintegrating tablet and preparation method thereof
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0502314A1 (en) 1991-02-06 1992-09-09 Dr. Karl Thomae GmbH Benzimidazol, medicaments containing them and process for their preparation
WO1999047123A1 (en) * 1998-03-18 1999-09-23 Bristol-Myers Squibb Company Pharmaceutical composition containing a statin and aspirin
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
WO2000043370A1 (en) 1999-01-19 2000-07-27 Boehringer Ingelheim Pharma Kg Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3025292A (en) * 1962-03-13 Reduction of i
US3163645A (en) † 1964-09-25 1964-12-29 Ciba Geigy Corp Derivatives of 3, 4-dihydro-2-h-[1, 2, 4]-benzothiadiazine-1, 1-dioxides
US5464854A (en) * 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
DE19539574A1 (en) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Preparations and processes for stabilizing biological materials by means of drying processes without freezing
US6087386A (en) * 1996-06-24 2000-07-11 Merck & Co., Inc. Composition of enalapril and losartan
EP0913177A1 (en) * 1997-11-03 1999-05-06 Roche Diagnostics GmbH Process for producing dry, amorphous products comprising biological active materials by means of convection drying technique, especially spray drying
US6413541B1 (en) * 1999-01-13 2002-07-02 Dainippon Pharmaceutical Co., Ltd. Disintegrating tablet in oral cavity and production thereof
AU1157500A (en) * 1998-11-06 2000-05-29 Boehringer Ingelheim International Gmbh Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof
US6358986B1 (en) † 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6737432B2 (en) * 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
EP1854454B1 (en) * 2002-01-16 2013-11-06 Boehringer Ingelheim Pharma GmbH & Co. KG Method for the preparation of amorphous telmisartan

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0502314A1 (en) 1991-02-06 1992-09-09 Dr. Karl Thomae GmbH Benzimidazol, medicaments containing them and process for their preparation
WO1999047123A1 (en) * 1998-03-18 1999-09-23 Bristol-Myers Squibb Company Pharmaceutical composition containing a statin and aspirin
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
WO2000043370A1 (en) 1999-01-19 2000-07-27 Boehringer Ingelheim Pharma Kg Telmisartan polymorphs, methods for producing same and their use in the preparation of a medicament

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LACOURCIERE Y ET AL: "COMPARISON OF THE ANTIHYPERTENSIVE EFFECTS OF A FIXED DOSE COMBINATION OF TELMISARTAN AND HYDROCHLOROTHIAZIDE VERSUS TELMISARTAN MONOTHERAPY IN MILD TO MODERATE HYPERTENSIVE PATIENTS", CANADIAN JOURNAL OF CARDIOLOGY, PULSUS GROUP, INC, XX, vol. 16, no. SUPPL F, September 2000 (2000-09-01), pages 107F, XP001053460, ISSN: 0828-282X *
LACOURSIERE ET AL., CAN J CARDIOL, vol. 16, 2000, pages 107F

Cited By (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9321791B2 (en) 2002-08-21 2016-04-26 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US9556175B2 (en) 2002-08-21 2017-01-31 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and thier use as pharmaceutical compositions
US10023574B2 (en) 2002-08-21 2018-07-17 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US10202383B2 (en) 2002-08-21 2019-02-12 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
HRP20050280B1 (en) * 2002-09-24 2014-01-03 Boehringer Ingelheim International Gmbh Solid pharmaceutical formulations comprising telmisartan
US8980870B2 (en) 2002-09-24 2015-03-17 Boehringer Ingelheim International Gmbh Solid telmisartan pharmaceutical formulations
WO2004028505A1 (en) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Solid pharmaceutical formulations comprising telmisartan
EA009237B1 (en) * 2002-09-24 2007-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Solid pharmaceutical formulations comprising telmisartan
US9744181B2 (en) 2003-01-14 2017-08-29 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US9457036B2 (en) 2003-01-14 2016-10-04 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
WO2005014043A1 (en) * 2003-07-16 2005-02-17 Boehringer Ingelheim International Gmbh Chlorthalidone combinations
WO2005082329A3 (en) * 2004-02-19 2006-04-13 Ranbaxy Lab Ltd Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
WO2005082329A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
US7501448B2 (en) 2004-10-15 2009-03-10 Teva Pharmaceutical Industries, Ltd. Process for preparing telmisartan
EP1807400A2 (en) * 2004-11-03 2007-07-18 Teva Pharmaceutical Industries, Inc. Amorphous and polymorphic forms of telmisartan sodium
WO2006048208A1 (en) * 2004-11-05 2006-05-11 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and amlodipine
US9751855B2 (en) 2004-11-05 2017-09-05 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
EP1814527B2 (en) † 2004-11-05 2020-11-18 Boehringer Ingelheim International GmbH Bilayer tablet comprising telmisartan and amlodipine
JP2008518888A (en) * 2004-11-05 2008-06-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Bilayer tablet containing telmisartan and amlodipine
EA013053B1 (en) * 2004-11-05 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Bilayer tablet comprising telmisartan and amlodipine
CN103083318A (en) * 2004-11-05 2013-05-08 贝林格尔.英格海姆国际有限公司 Bilayer tablet comprising telmisartan and amlodipine
US9499546B2 (en) 2004-11-05 2016-11-22 Boehringer Ingelheim International Gmbh Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines
JP2008524136A (en) * 2004-12-17 2008-07-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Combination therapy with telmisartan and hydrochlorothiazide
WO2006063737A1 (en) * 2004-12-17 2006-06-22 Boehringer Ingelheim International Gmbh Combination therapy comprising telmisartan and hydrochlorothiazide
US9018192B2 (en) 2005-06-13 2015-04-28 Bristol-Myers Squibb & Gilead Sciences, Inc. Unitary pharmaceutical dosage form
US9545414B2 (en) 2005-06-13 2017-01-17 Bristol-Myers Squibb & Gilead Sciences, Llc Unitary pharmaceutical dosage form
US8871271B2 (en) 2005-06-13 2014-10-28 Gilead Sciences, Inc. Method and composition for pharmaceutical product
WO2007001067A3 (en) * 2005-06-27 2007-07-12 Daiichi Sankyo Co Ltd Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
EP1797872A1 (en) * 2005-11-22 2007-06-20 Teva Pharmaceutical Industries Ltd Telmisartan-containing pharmaceutical compositions for oral intake
WO2007061415A1 (en) * 2005-11-22 2007-05-31 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions of telmisartan
WO2007060170A3 (en) * 2005-11-24 2007-09-13 Boehringer Ingelheim Int Bilayer tablet comprising telmisartan and diuretic
WO2007060170A2 (en) * 2005-11-24 2007-05-31 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
US11084819B2 (en) 2006-05-04 2021-08-10 Boehringer Ingelheim International Gmbh Polymorphs
US11919903B2 (en) 2006-05-04 2024-03-05 Boehringer Ingelheim International Gmbh Polymorphs
US11291668B2 (en) 2006-05-04 2022-04-05 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US11033552B2 (en) 2006-05-04 2021-06-15 Boehringer Ingelheim International Gmbh DPP IV inhibitor formulations
US10080754B2 (en) 2006-05-04 2018-09-25 Boehringer Ingelheim International Gmbh Uses of DPP IV inhibitors
US9815837B2 (en) 2006-05-04 2017-11-14 Boehringer Ingelheim International Gmbh Polymorphs
US10301313B2 (en) 2006-05-04 2019-05-28 Boehringer Ingelheim International Gmbh Polymorphs
US9493462B2 (en) 2006-05-04 2016-11-15 Boehringer Ingelheim International Gmbh Polymorphs
US8956662B2 (en) 2006-06-01 2015-02-17 Msd Consumer Care, Inc. Phenylephrine pharmaceutical formulations and compositions for colonic absorption
US20140134247A1 (en) * 2006-06-16 2014-05-15 Lek Pharmaceuticals D.D. Pharmaceutical composition
WO2007144175A3 (en) * 2006-06-16 2008-10-02 Lek Pharmaceuticals Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
WO2007144175A2 (en) 2006-06-16 2007-12-21 Lek Pharmaceuticals D.D. Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
US9622976B2 (en) 2006-06-16 2017-04-18 Lek Pharmaceuticals D.D. Pharmaceutical composition
EP2269583A1 (en) 2006-06-16 2011-01-05 LEK Pharmaceuticals d.d. Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
US8685452B2 (en) 2006-06-16 2014-04-01 Lek Pharmaceuticals D.D. Pharmaceutical composition
EP2037893A2 (en) * 2006-06-27 2009-03-25 Novartis AG Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
WO2008044862A1 (en) * 2006-10-10 2008-04-17 Hanall Pharmaceutical Co., Ltd. Combined preparation for the treatment of cardiovascular diseases based on chronotherapy theory
KR100888131B1 (en) 2006-10-10 2009-03-11 한올제약주식회사 Combination preparation for Cardiovascular disease therapy by Chronotherapy theory.
EA018574B1 (en) * 2007-03-14 2013-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Pharmaceutical composition
TWI406678B (en) * 2007-03-14 2013-09-01 Boehringer Ingelheim Int Pharmaceutical tablet or tablet layer and manufacturing method thereof
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
WO2008110599A1 (en) * 2007-03-14 2008-09-18 Boehringer Ingelheim International Gmbh Pharmaceutical composition
EP2203158A2 (en) 2007-10-30 2010-07-07 Dr. Reddy's Laboratories, Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
EP2203158A4 (en) * 2007-10-30 2012-12-26 Reddys Lab Ltd Dr Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
US8968769B2 (en) 2007-10-31 2015-03-03 Mcneil-Ppc, Inc. Orally disintegrative dosage form
WO2009115301A1 (en) * 2008-03-19 2009-09-24 Ratiopharm Gmbh Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
EP2252273B1 (en) 2008-03-19 2016-12-28 ratiopharm GmbH Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic
US9415016B2 (en) 2008-04-03 2016-08-16 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10022379B2 (en) 2008-04-03 2018-07-17 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10973827B2 (en) 2008-04-03 2021-04-13 Boehringer Ingelheim International Gmbh DPP-IV inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
US10034877B2 (en) 2008-08-06 2018-07-31 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US9486526B2 (en) 2008-08-06 2016-11-08 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients inappropriate for metformin therapy
US11911388B2 (en) 2008-10-16 2024-02-27 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
WO2010057449A2 (en) 2008-11-24 2010-05-27 Zentiva, K.S. A solid pharmaceutical composition with atorvastatin and telmisartan as the active substances
WO2010075347A3 (en) * 2008-12-23 2010-08-19 Takeda Pharmaceutical Company Limited Treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
WO2010081824A2 (en) 2009-01-14 2010-07-22 Lek Pharmaceuticals D.D. Active coating of pharmaceutical dosage forms
EP2210595A1 (en) 2009-01-14 2010-07-28 LEK Pharmaceuticals d.d. Active coating of pharmaceutical dosage forms
WO2010146187A2 (en) 2009-06-19 2010-12-23 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
US8807979B2 (en) 2009-09-24 2014-08-19 Mcneil-Ppc, Inc. Machine for the manufacture of dosage forms utilizing radiofrequency energy
US8858210B2 (en) 2009-09-24 2014-10-14 Mcneil-Ppc, Inc. Manufacture of variable density dosage forms utilizing radiofrequency energy
US9610224B2 (en) 2009-09-24 2017-04-04 Johnson & Johnson Consumer Inc. Manufacture of tablet in a die utilizing powder blend containing water-containing material
US8865204B2 (en) 2009-09-24 2014-10-21 Mcneil-Ppc, Inc. Manufacture of lozenge product with radiofrequency
US8871263B2 (en) 2009-09-24 2014-10-28 Mcneil-Ppc, Inc. Manufacture of tablet in a die utilizing radiofrequency energy and meltable binder
US8784781B2 (en) 2009-09-24 2014-07-22 Mcneil-Ppc, Inc. Manufacture of chewing gum product with radiofrequency
US9107807B2 (en) 2009-09-24 2015-08-18 Mcneil-Ppc, Inc. Machine for the manufacture of dosage forms utilizing radiofrequency energy
US9457029B2 (en) 2009-11-27 2016-10-04 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US10092571B2 (en) 2009-11-27 2018-10-09 Boehringer Ingelheim International Gmbh Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
US9603851B2 (en) 2010-05-05 2017-03-28 Boehringer Ingelheim International Gmbh Combination therapy
US10004747B2 (en) 2010-05-05 2018-06-26 Boehringer Ingelheim International Gmbh Combination therapy
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
US20110318411A1 (en) * 2010-06-24 2011-12-29 Luber Joseph R Multi-layered orally disintegrating tablet and the manufacture thereof
AU2011306063B2 (en) * 2010-09-22 2015-03-12 Mcneil-Ppc, Inc. Multi-layered orally disintegrating tablet and the manufacture thereof
US11911387B2 (en) 2010-11-15 2024-02-27 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
WO2013050339A1 (en) 2011-10-03 2013-04-11 Ems S/A Pharmaceutical compositions of antihypertensives
EP2612658A1 (en) 2012-01-05 2013-07-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
WO2013102651A1 (en) 2012-01-05 2013-07-11 Laboratorios Lesvi, S.L. Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
US10195203B2 (en) 2012-05-14 2019-02-05 Boehringr Ingelheim International GmbH Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9526730B2 (en) 2012-05-14 2016-12-27 Boehringer Ingelheim International Gmbh Use of a DPP-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
US9713618B2 (en) 2012-05-24 2017-07-25 Boehringer Ingelheim International Gmbh Method for modifying food intake and regulating food preference with a DPP-4 inhibitor
WO2014026261A1 (en) * 2012-08-17 2014-02-20 Hypermarcas S.A. Solid oral pharmaceutical preparation for preventing cerebrovascular and heart diseases, and tablet
US9789066B2 (en) 2014-01-10 2017-10-17 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
KR20170001921A (en) 2015-06-26 2017-01-05 대원제약주식회사 A pharmaceutical composition comprising telmisartan with increased stability and a preparation method thereof
KR20170012703A (en) 2015-07-22 2017-02-03 대원제약주식회사 A pharmaceutical composition comprising telmisartan and a preparation method thereof
WO2017207375A1 (en) 2016-05-30 2017-12-07 Boehringer Ingelheim International Gmbh Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
US10155000B2 (en) 2016-06-10 2018-12-18 Boehringer Ingelheim International Gmbh Medical use of pharmaceutical combination or composition
WO2018084627A3 (en) * 2016-11-03 2018-07-26 Hanmi Pharm. Co., Ltd. Pharmaceutical complex formulation comprising amlodipine, losartan and chlorthalidone
CN106749037B (en) * 2016-12-21 2019-06-21 山东大学 A kind of unformed Telmisartan-glutaric acid eutectic and its preparation method and application
CN106749036B (en) * 2016-12-21 2019-06-21 山东大学 A kind of unformed Telmisartan-pimelic acid eutectic and its preparation method and application
CN106749036A (en) * 2016-12-21 2017-05-31 山东大学 A kind of unformed Telmisartan pimelic acid eutectic and its preparation method and application
CN106749037A (en) * 2016-12-21 2017-05-31 山东大学 A kind of unformed Telmisartan glutaric acid eutectic and its preparation method and application
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US20230111273A1 (en) * 2020-12-10 2023-04-13 Novitium Pharma LLC Hydrochlorothiazide compositions
US11878022B2 (en) * 2020-12-10 2024-01-23 Novitium Pharma LLC Hydrochlorothiazide compositions
WO2023001880A1 (en) 2021-07-22 2023-01-26 Krka, D. D., Novo Mesto Bilayer tablet comprising telmisartan and indapamide

Also Published As

Publication number Publication date
ES2298351T5 (en) 2012-01-26
ES2298351T3 (en) 2008-05-16
AU2002242676B2 (en) 2008-05-29
ME02761B (en) 2011-05-10
DE60224096T2 (en) 2008-04-17
CN101352421A (en) 2009-01-28
HRP20040649B1 (en) 2012-12-31
DE60224096D1 (en) 2008-01-24
CA2472392A1 (en) 2003-07-24
AU2002242676A1 (en) 2003-07-30
KR20080016757A (en) 2008-02-21
HK1073785A1 (en) 2005-10-21
ES2400138T3 (en) 2013-04-05
NO345891B1 (en) 2021-09-27
US20130309307A1 (en) 2013-11-21
CY1114890T1 (en) 2016-12-14
IL162754A (en) 2012-10-31
EP2260833A3 (en) 2011-06-01
HUP0501086A3 (en) 2008-03-28
PT2260833E (en) 2012-12-26
CA2651604C (en) 2013-04-09
CA2651604A1 (en) 2003-07-24
CA2472392C (en) 2009-07-14
EP2260833A2 (en) 2010-12-15
DK1854454T3 (en) 2014-01-13
EA200400879A1 (en) 2005-02-24
EA200601917A1 (en) 2007-06-29
HUP0501086A2 (en) 2007-09-28
DK1467712T4 (en) 2011-11-21
SK2902004A3 (en) 2004-11-03
IL219481A0 (en) 2012-06-28
NO20171988A1 (en) 2004-08-11
BR0215514A (en) 2004-12-21
NO20140821L (en) 2004-08-11
BG67075B1 (en) 2020-05-29
CN100571695C (en) 2009-12-23
JP4181503B2 (en) 2008-11-19
JP2008285501A (en) 2008-11-27
DK1467712T3 (en) 2008-01-21
HRP20040649A2 (en) 2005-06-30
CZ303145B6 (en) 2012-05-02
NO342634B1 (en) 2018-06-25
JP4929241B2 (en) 2012-05-09
DK2260833T3 (en) 2013-01-07
EP1854454A3 (en) 2010-01-13
ATE380547T1 (en) 2007-12-15
IL219481A (en) 2014-06-30
CZ2004939A3 (en) 2005-02-16
AU2008203182A1 (en) 2008-08-07
BG112153A (en) 2016-04-28
AU2008203182B2 (en) 2010-04-29
KR100876302B1 (en) 2008-12-31
SI1467712T1 (en) 2008-04-30
EP2260833B1 (en) 2012-11-21
EA007614B1 (en) 2006-12-29
CY1107226T1 (en) 2012-11-21
IL194933A0 (en) 2009-08-03
JP2005514439A (en) 2005-05-19
PT1854454E (en) 2014-01-09
BG66588B1 (en) 2017-07-31
MXPA04006997A (en) 2004-12-07
NO20043344L (en) 2004-08-11
EA012329B1 (en) 2009-08-28
EP1467712B1 (en) 2007-12-12
EP1854454A2 (en) 2007-11-14
NZ534502A (en) 2007-03-30
IL162754A0 (en) 2005-11-20
HU229941B1 (en) 2015-01-28
SI1467712T2 (en) 2011-11-30
UA78273C2 (en) 2007-03-15
US20090227802A1 (en) 2009-09-10
IL194933A (en) 2015-02-26
SK288439B6 (en) 2017-01-03
CY1114929T1 (en) 2016-12-14
NO336167B1 (en) 2015-06-01
BG112220A (en) 2016-12-30
MEP42408A (en) 2011-02-10
PT1467712E (en) 2008-01-09
US20050089575A1 (en) 2005-04-28
EP1467712A1 (en) 2004-10-20
RS61104A (en) 2006-10-27
KR100851770B1 (en) 2008-08-13
EP1467712B2 (en) 2011-08-31
ES2445041T3 (en) 2014-02-27
EP1854454B1 (en) 2013-11-06
CN1615123A (en) 2005-05-11
RS52012B (en) 2012-04-30
KR20040079937A (en) 2004-09-16
BG108781A (en) 2005-03-31
BG66524B1 (en) 2016-04-28
DE60224096T3 (en) 2012-01-12

Similar Documents

Publication Publication Date Title
CA2472392C (en) Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
US8637078B2 (en) Bilayer tablet comprising telmisartan and diuretic
IL167610A (en) Solid pharmaceutival formulations comprising telmisartan
WO2005079762A1 (en) Multilayer tablet
KR20080100292A (en) A method for the preparation of substantially amorphous telmisartan

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200400745

Country of ref document: VN

Ref document number: P-611/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 162754

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 108781

Country of ref document: BG

Ref document number: 10878102

Country of ref document: BG

WWE Wipo information: entry into national phase

Ref document number: 2002708290

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1928/DELNP/2004

Country of ref document: IN

Ref document number: 2472392

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: P20040649A

Country of ref document: HR

Ref document number: 20028271823

Country of ref document: CN

Ref document number: 10892425

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2902004

Country of ref document: SK

Ref document number: 2003559490

Country of ref document: JP

Ref document number: 1-2004-501074

Country of ref document: PH

Ref document number: 1020047011113

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/006997

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 200400879

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 534502

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002242676

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20040316

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2004-939

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2002708290

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2004-939

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 2002708290

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020087003317

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 194933

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020087026835

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 219481

Country of ref document: IL